ClinicalTrials.gg

Program

Piroxicam

Also written as “Piroxicam ( BAYl1902)”, “Piroxicam plus Counterirritant (brand name Counterpain® PXM).” and “Felden (piroxicam) Tablets”.

Its studies are mostly in Ankle Injuries · Pain · Dysmenorrhea, led by 4 companies.

Furthest: phase 4, since Mar 21, 20114 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayer10 open or runningphase 2since Mar 21, 2011Mar 21, 2011none ahead
Nanoform Finland10 open or runningphase 1since Mar 28, 2021Mar 28, 2021none ahead
Pfizer10 open or runningphase 4since Mar 28, 2008Mar 28, 2008none ahead
Taisho Pharmaceutical10 open or runningphase 3since Feb 19, 2026Feb 19, 2026none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 28, 2008First study: phase 4 study in DysmenorrheaNew to PfizerPfizer · NCT00649415 · 154 enrolled · Brazil
  2. Mar 21, 2011Bayer's first study: phase 2 study in Contraception, PostcoitalNew to BayerBayer · NCT01320709 · 72 enrolled · Germany
  3. Mar 28, 2021Nanoform Finland's first study: phase 1 study in PainNew to Nanoform FinlandNanoform Finland · NCT05104931 · 12 enrolled · United Kingdom
  4. Feb 19, 2026Taisho Pharmaceutical's first study: phase 3 study in Ankle InjuriesNew to Taisho PharmaceuticalTaisho Pharmaceutical · NCT07475663 · 180 enrolled · Indonesia

TargetBeta

PTGS1 →PTGS2 →read by rule
“Cyclooxygenase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
AcetaminophenruleJohnson & Johnsonphase 4136
IbuprofenrulePfizerphase 4113
AspirinruleBayerphase 484
dexketoprofenruleMenarini Groupphase 48
SulfasalazineruleBristol-Myers Squibbphase 47
dexibuprofenruleaponia-laboratories-incphase 46
BenzydamineruleAngelini Pharmaphase 44
DipyroneruleHypera Pharmaphase 44
FlurbiprofenruleGlaxoSmithKlinephase 312

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07475663Ankle Injuries · Indonesia3CompletedTaisho PharmaceuticalFeb 12, 2026180
NCT05104931Pain · United Kingdom1CompletedNanoform FinlandFeb 1, 202112
NCT01320709Contraception, Postcoital · Germany2CompletedBayerMar 201272
NCT00649415Dysmenorrhea · Brazil4CompletedPfizer154

How it is read

Names in the registry

  • “Piroxicam ( BAYl1902)”, 3 entries
  • “Piroxicam plus Counterirritant (brand name Counterpain® PXM).”, 1 entry
  • “Felden (piroxicam) Tablets”, 1 entry
  • “Brexidol (piroxicam) Tablets”, 1 entry
  • “piroxicam”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.